Revisiting the Pharmacoeconomics of HF

Slides:

Advertisements

Similar presentations

Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.

Advertisements

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Beta-Blockers and Outcome in Heart Failure and Atrial.

Upfront Combination Therapy vs Step-Up Approach for PAH:

Symptom Control and Enhancing Functioning in Schizophrenia

CLINICAL DILEMMAS IN HEART FAILURE:

Emerging Concepts in Heart Failure

EMPHASIS-HF Extended Follow-up

Hospitalizations and Healthcare Costs Need for Reduction in Hospitalizations of Patients With HF

ICD-10 and Clinical Documentation

Optimizing Statin Therapy

NOACs for Cancer-Associated Thrombosis:

Heart Failure and Hospital Readmissions

Heart Rate, HF Admissions, and Readmissions

A CASE CHALLENGE IN HFrEF:

Patient-Centered Care in Cystic Fibrosis

Update on NSAID Use:.

Cost Effectiveness and Optimal Outcomes in HF

Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.

Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.

Heart Failure Prevention: Mission Impossible?

Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?

PAH Therapy Revisited.

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

Treating HFrEF: Challenges Faced

Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.

Are We Closer to Personalized Medicine in MS?

A Pharmacist's Guide to PCSK9 Inhibitors:

Preventing Heart Failure Readmission and Progression

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

From Start to Finish: Initial and Ongoing Care for Men Receiving PrEP

Risk Stratification in CAD and PAD

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

Remote Patient Management:

Evaluating New Therapies in HF

A PCP's Guide to Dyslipidemia

The Importance of Getting the Dose Right in HF

Innovations in Home Care

Using Heart Rate as a Biomarker in Clinical Practice.

Introduction. Clinical Scenario: Encouraging Adherence in Patients with Schizophrenia.

Updates in Heart Failure:

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

Challenging the Myths in Heart Failure With Reduced Ejection Fraction

When Is Intrathecal Drug Delivery Appropriate?

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

CAD and HF Often Coexist

New Strategies to Reduce HF Readmissions

Communicating With Your Patients About Major Depressive Disorder

Program Goals Background: Anticoagulation in Patients With VTE.

Improving Adherence to Antiplatelet Therapy After an ACS Event

Live on PAH: Breathing Life Into Patients With PAH

Assessing the Burden of Hyperkalemia

When Is Intrathecal Drug Delivery Appropriate?

HF-Related Hospitalization and Readmissions

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Assessing the Burden of Hyperkalemia

AHF Epidemiology Readmissions Reduction Program.

Updates on Dyslipidemia

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Uptitration of Medications in HF: Start Low but Aim High and Stay High

In-Hospital Treatment for Heart Failure: New Approaches and a Renewed Sense of Hope?

Recurrence of HF hospitalization Total-time approach

My PAH Patient.

Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.

Top Tips in Evidence-Based Care for HFrEF

Key Data on Improving Outcomes in HF Patients

Case Study #1. Management of Heart Failure With Comorbidities: Challenging Cases for the Cardiologist.

Fresh perspectives ON BASAL Insulins in diabetes care

Presentation transcript:

Revisiting the Pharmacoeconomics of HF

Program Goals

Need for Reduction in Hospitalizations of HF

Need for Reduction in Costs Associated With HF

A Large Number of Eligible Patients Are Untreated

The Importance of Considering Cost-Effectiveness

New Therapies for HF

Measuring Cost-Effectiveness

Measuring Cost-Effectiveness (cont)

Cost-Effectiveness of Ivabradine Greece and United Kingdom

Cost-Effectiveness of Ivabradine United States

Cost-Effectiveness of Sacubitril/ Valsartan

Cost-Effectiveness of Sacubitril/ Valsartan (cont)

Cost-Effectiveness of Sacubitril/ Valsartan (cont)

Ivabradine and Sacubitril/Valsartan Decrease Risk of Recurrent Hospitalizations for Worsening HF

The Lapse Between Research and Clinical Practice

Bringing New Drugs Into Clinical Care

Abbreviations